Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon, Tudor–Eliade Ciuleanu, Oscar G. Arrieta et al. · The Lancet · 2014
Cited by 1,306 works. doi:10.1016/s0140-6736(14)60845-x
Authors
- Edward B. Garon
- Tudor–Eliade Ciuleanu
- Oscar G. Arrieta
- Kumar Prabhash
- Konstantinos Nikolaos Syrigos
- Tuncay Göksel
- Keunchil Park
- Vera A. Gorbunova
- Rubén Dario Kowalyszyn
- Joanna Pikiel
- Grzegorz Czyżewicz
- С. В. Орлов
- Conrad R. Lewanski
- Michael Thomas
- Paolo Bidoli
- Shaker R. Dakhil
- Steven J.M. Gans
- Joo-Hang Kim
- Alexandru Călin Grigorescu
- Nina A. Karaseva
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- The Hallmarks of Cancer
- EuroQol - a new facility for the measurement of health-related quality of life
- Cancer statistics, 2012
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer